The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...

As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second deal this year to expand its presence in rare diseases.

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest clinical move targets a niche but ...

Rare neurological diseases offer unusually clear models for testing earlier diagnosis, precision treatment and long-term ...

Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. During the early episodes of Grey's Season 2, much of the drama was surrounding Addison's arrival ...

There are long-running TV shows, and then there's Grey's Anatomy. The ABC medical drama is one of the longest-running TV shows of all time and during the run Grey's has had wild medical cases, ...